US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% MSTR $160.01 ▲+0.00%
FinancialContent

Articles published by BioNxt Solutions Inc.

News headline image
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
News headline image
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
News headline image
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT